Last reviewed · How we verify
NCT04155827
Gender Specific Responses of Overweight and Obese Adults to Sprint Interval Training
NA trial testing SIT in Overweight and Obesity in 35 participants. Completed in 23 November 2020.
16 November 2020
Quick facts
| Lead sponsor | Universiti Tunku Abdul Rahman |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 4 February 2020 |
| Primary completion | 16 November 2020 |
| Estimated completion | 23 November 2020 |
| Sites | 1 location across Malaysia |
Drugs / interventions tested
- SIT
Conditions studied
- Overweight and Obesity — all drugs for Overweight and Obesity →
Sponsor
Universiti Tunku Abdul Rahman
Who can join
Adults 18 to 25, any sex, with Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Overweight and Obesity is a growing health problem worldwide. Lifestyle changes such as decreased physical activity, increased sedentary behaviour and unhealthy eating habits has contribute to this problem. According to World Health Organization (2016), more than 1.9 billion adults aged 18 years and older were overweight (39% of men and 40% of women).Regular exercise is the key contributor to energy expenditure and is essential for energy balance and weight control. Interval training (IT) has been commonly used for decades with purpose to improve body health and reduce weight loss and this exercise differs from the conventional aerobic exercise and endurance exercise as IT typically involves repeated bouts of relatively intense exercise interspersed by periods of lower- intensity effort or complete rest for recovery. One of the most common type of IT is sprint interval training (SIT). SIT involves 'supramaximal' effort (\>100% VO2max) work bouts, traditionally structured as four to six 30s all-out effort and each round separated by 4 minutes of recovery period of a low intensity exercise. Potential physiological adaptation of SIT are highlighted by various studies reporting cardiovascular, skeletal muscle adaptations, increase fat oxidation that facilitate increases in both aerobic and anaerobic performance. In addition, SIT is able to improve maximal rate of oxygen consumption (VO2max), at the same time improving the peripheral vascular structure and function, enzymes of fat metabolism and increases insulin sensitivity. Previous SIT studies have included young healthy men and women, healthy obese young women, all of which have shown that SIT is effective for fat loss and improvement of some health parameters. However, whether SIT protocol is equally effective in improving the anthropometric measures in men and women remain unknown.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04155827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SIT
Trials testing the same drug.
- NCT06656780 — Stress Inoculation Training (SIT): An Evidence-Based, Military Aligned Psychological Performance and Health Sustainment · NA · not yet recruiting
- NCT06664281 — Effects of SIT Combined with Remote Ischemic Preconditioning on Vascular Function in Young Women with Masked Obesity · NA · completed
- NCT06658509 — Regulation of Different IT on Vascular Function of Overweight Female University Students · NA · completed
- NCT04195165 — The Effect of Sitting and Moderate Exercise on Plasma Insulin and Glucose Responses to an Oral Glucose Tolerance Test · NA · unknown
- NCT03888508 — Comparison of Efficacy of Sensory Integration Therapy in Children With Cerebral Palsy · NA · completed
Other recruiting trials for Overweight and Obesity
Currently open trials in the same condition.
- NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
- NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
Other Universiti Tunku Abdul Rahman trials
Trials by the same sponsor.
- NCT07024511 — Effectiveness of Auricular Acupuncture for Migraine · NA · not yet recruiting
- NCT07038499 — Prevalence and Determinants of Migraine Among Headache Patients · not yet recruiting
- NCT07092878 — Effects of Chamomile With L-theanine Beverage Among Young Women Experiencing Primary Dysmenorrhea · NA · recruiting
- NCT06724419 — Efficacy of Nutrition Education in Alleviating Premenstrual Syndrome (PMS) Among Chinese College Students at Hainan Univ · NA · completed
- NCT05533268 — Effect of Mental and Physical Training on Blood Pressure · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04155827 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universiti Tunku Abdul Rahman
- Last refreshed: 24 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04155827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing